Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18706184 | 1.00 | KDM4E (0.46) | KDM4ESMN1; SMN2CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL29115046 | 0.85 | KDM4E (0.44) | KDM4ESMN1; SMN2ALDH1A1LMNABCAT1 | |
| SCHEMBL29115049 | 0.85 | KDM4E (0.44) | KDM4ESMN1; SMN2ALDH1A1LMNABCAT1 | |
| SCHEMBL29115043 | 0.85 | KDM4E (0.44) | KDM4ESMN1; SMN2ALDH1A1LMNABCAT1 | |
| SCHEMBL12031316 | 0.75 | — | — | |
| SCHEMBL3031343 | 0.75 | — | — | |
| SCHEMBL15043322 | 0.75 | — | — | |
| SCHEMBL3031341 | 0.75 | — | — | |
| SCHEMBL18211354 | 0.73 | THRB (0.55) | KDM4ESMN1; SMN2CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL13963966 | 0.73 | THRB (0.55) | KDM4ESMN1; SMN2CYP1A2CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022266758-A1 | CELL-SURFACE ENGINEERING COMPOSITIONS AND METHODS FOR THE PREVENTION OF IMMUNE REJECTION | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-12-29 | — | — | WO | disclosed |
| EP-3359537-B1 | TRIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-03-25 | — | — | EP | disclosed |
| US-10273217-B2 | Triazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180237401-A1 | TRIAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-08-23 | — | — | US | disclosed |
| WO-2017060202-A1 | TRIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180237401-A1 | TRIAZOLE DERIVATIVES | MC2R, MC3R, OXTR | KDM4E 2864/4885SMN1; SMN2 3878/4885CYP1A2 720/4885 |
| US-10273217-B2 | Triazole derivatives | MC2R, MC3R, OXTR | KDM4E 2864/4885SMN1; SMN2 3878/4885CYP1A2 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.